An observational study in Ocular Toxoplasmosis, sponsored by Hospices Civils de Lyon. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2019-05-14.
Sponsored by Hospices Civils de Lyon · Observational
Ocular toxoplasmosis (OT) is a common cause of posterior uveitis worldwide. The diagnosis of OT is based on clinical findings, but in most cases, laboratory tests are required to confirm the etiology, especially when other diseases are suspected. The aim of this study was to evaluate which methods, between the Goldmann-Witmer coefficient (GWC) and immunoblotting (IB) with both IgG and IgA, in aqueous humour (AH) samples, can be the most sensitive to diagnose OT, in current practice, especially in the first three weeks.
Goldmann-Witmer coefficient (GWC): compares the levels of intraocular antibody (igG) production to that serum, as measured by ELISA.
GWC = (Level of specific IgG in aqueous humour/level of specific IgG in serum)/(Total IgG in aqueous humour/Total IgG in serum)
0.5 to 2: No intraocular antibody production, 2 to 4: Suggestive of intraocular antibody production, > 4: Diagnostic of intraocular antibody production to a specific microbial pathogen
36 studies on the registry are indexed under Toxoplasmosis; 9 are open to participants now.
This study's enrollment of 87 is below the median of 100 across 13 observational studies indexed under Toxoplasmosis.
Browse Toxoplasmosis studies →Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who had underwent aqueous humor and serum sample for ocular toxoplasmosis
Exclusion Criteria:
Procedure: Aqueous humour sampling
Procedure: Aqueous humour sampling
Aqueous humour sampling with Goldman-Witmer coefficient and immunoblotting
Comparison of Goldmann-Witmer coefficient and immunoblotting results
All tests realized in patients were performed before their repartition in the two groups as well as the biologist could not know the status of the patient. Sensitivity and specificity were calculated for each test.
Time frame: Assessment of each test result at the inclusion of the patient
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospices Civils de Lyon